公开(公告)号：KR1020070006497A

公开(公告)日：2007-01-11

申请号：KR1020050061884

申请日：2005-07-08

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식 ,  문상옥

IPC: A61K31/4523 ,  A61K31/454 ,  A61K31/4535

CPC classification number: A61K31/4439 ,  A61K9/0012 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/10 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/426

Abstract: A pharmaceutical composition comprising rosiglitazone is provided to be useful for decreasing renal disorders caused by sepsis, thereby being applied as a material useful for developing therapeutic agents effective for decreasing death rate and symptoms of a disease. The pharmaceutical composition for inhibiting renal disorders comprises rosiglitazone represented by the formula(1), a salt thereof or a derivative thereof. In the formula(1), each A and A' is independently Co N, R1 is C1-5 alkyl or H, and R2 is C1-5 alkyl, H, or hydroxy.

Abstract translation: 提供包含罗格列酮的药物组合物可用于减少由败血症引起的肾脏疾病，从而作为可用于开发有效降低死亡率和疾病症状的治疗剂的材料。 用于抑制肾脏疾病的药物组合物包括由式（1）表示的罗格列酮，其盐或其衍生物。 在式（1）中，A和A'各自独立地是Co N，R 1是C 1-5烷基或H，R 2是C 1-5烷基，H或羟基。

公开(公告)号：KR100847751B1

公开(公告)日：2008-07-22

申请号：KR1020070042754

申请日：2007-05-02

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식

IPC: A61K38/17 ,  A61P13/12 ,  A61P3/10

CPC classification number: A61K38/17 ,  Y10S514/866

Abstract: A pharmaceutical composition comprising COMP-Ang1(cartilage oligomeric matrix protein-angiopoietin-1) is provided to inhibit inflammation and regulate sugar and lipid metabolism, so that the composition is useful for treatment of diabetic nephropathy. A pharmaceutical composition for treatment of diabetic nephropathy comprises COMP-Ang1 and is administered orally or parenterally, wherein the COMP-Ang1 is prepared by replacing a coiled coil domain in a native angiopoietin-1 gene by cartilage oligomeric matrix protein, inserting the recombinant angiopoietin-1 gene into CHO(Chinese hamster ovary cell) cell line, and culturing the recombinant CHO cell line; the oral composition is formulated as tablet, pill, powder, granule, syrup, solution, suspension, emulsion or capsule, and the parenteral composition is formulated as injection, transrectal enteric preparations or transdermal preparations.

Abstract translation: 提供了包含COMP-Ang1（软骨低聚基质蛋白 - 血管生成素-1）的药物组合物以抑制炎症并调节糖和脂质代谢，使得该组合物可用于治疗糖尿病性肾病。 用于治疗糖尿病肾病的药物组合物包括COMP-Ang1并口服或非肠道给药，其中COMP-Ang1通过用软骨寡聚基质蛋白替代天然血管生成素-1基因中的卷曲螺旋结构域，将重组血管生成素 - 1基因转入CHO（中国仓鼠卵巢细胞）细胞系，培养重组CHO细胞系; 口服组合物配制成片剂，丸剂，粉剂，颗粒剂，糖浆剂，溶液剂，悬浮液，乳剂或胶囊剂，肠胃外组合物配制成注射剂，经直肠制剂或透皮制剂。

公开(公告)号：KR1020070032156A

公开(公告)日：2007-03-21

申请号：KR1020050087096

申请日：2005-09-16

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식 ,  문상옥

IPC: A61K31/05

Abstract: 본 발명은 레스베라트롤을 유효성분으로 함유하는 약제학적 조성물에 관한 것으로, 레스베라트롤은 프랙트알킨 발현의 저해제로서, TNF-α의 유도로 인한 염증 모델의 동맥 상피세포에서 프랙트알킨의 발현과 단핵세포에 대한 내피세포의 부착을 감소시키므로 염증을 경감시키는 효과를 갖는다.
레스베라트롤, 프랙트알킨, 내피세포, 염증

公开(公告)号：KR1020070036450A

公开(公告)日：2007-04-03

申请号：KR1020050091476

申请日：2005-09-29

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식 ,  문상옥

IPC: A61K31/385 ,  A61K31/095

CPC classification number: A61K31/385

Abstract: The present invention relates to a pharmaceutical composition containing alpha-lipoic acid (LA) as an active ingredient. alpha-lipoic acid is an inhibitor of fractalkine expression, and exhibits effects of alleviating inflammation due to endotoxemia by decreasing expression of fractalkine and attachment of endothelial cells to monocytes in endothelial cells of an LPS-induced endotoxemia model.

公开(公告)号：KR100794391B1

公开(公告)日：2008-01-15

申请号：KR1020070011205

申请日：2007-02-02

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식

IPC: A61K38/39 ,  A61P13/12

CPC classification number: A61K38/39 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/2022

Abstract: A pharmaceutical composition comprising cartilage oligomeric matrix protein-angiopoietin-1 is provided to be used for treating the damage of endothelial cells and kidney fibrosis by protecting kidney endothelial cells. A pharmaceutical composition for treating unilateral ureteral obstruction comprises cartilage oligomeric matrix protein-angiopoietin-1. The composition is an oral formulation such as tablet, pill, powder, granule, syrup, liquid, suspension, emulsion and capsule or a non-oral formulation such as injection, transrectal formulation and transdermal formulation.

Abstract translation: 提供包含软骨低聚基质蛋白 - 血管生成素-1的药物组合物，用于通过保护肾内皮细胞来治疗内皮细胞和肾纤维化的损伤。 用于治疗单侧输尿管梗阻的药物组合物包括软骨低聚基质蛋白 - 血管生成素-1。 组合物是口服制剂，例如片剂，丸剂，粉剂，颗粒剂，糖浆剂，液体剂，悬浮剂，乳剂和胶囊剂或非口服制剂如注射剂，经直肠制剂和透皮制剂。